Home › Funds › Taproot Management LP › RPRX
Taproot Management LP position in RPRX
ROYALTY PHARMA PLC · Health Care
Taproot Management LP reported holding 129,592 shares of RPRX (ROYALTY PHARMA PLC) in its Q1 2026 13F filing — a position valued at US$6.2M, representing 1.17% of its reported portfolio and ranking #16 among its reported holdings. Taproot Management LP has disclosed RPRX holdings in 2 of the last 2 reported quarters, going back to Q4 2025.
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
How Taproot Management LP's RPRX position evolved
Taproot Management LP first disclosed a stake in RPRX in Q4 2025 at 284,687 shares (US$11.0M). Across 2 filings, Taproot Management LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q1 2026) shows 129,592 shares valued at US$6.2M — a reduction of -155,095 shares quarter over quarter.. Notable position changes include a 54% trim in Q1 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 284.69K | $11.00M | New |
| Q1 2026 | 129.59K | $6.22M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 50 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.73M sh · $601.44M · Q2 2026
- Baillie Gifford & Co 10.02M sh · $561.57M · Q2 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 4.32M sh · $242.20M · Q2 2026
- Patient Capital Management, LLC 3.60M sh · $201.79M · Q2 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 2.39M sh · $133.78M · Q2 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $92.92M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $77.67M · Q2 2026
More on Taproot Management LP
FAQ
How long has Taproot Management LP held RPRX?
Taproot Management LP has disclosed RPRX holdings in 2 of the last 2 reported quarters, going back to Q4 2025.
What is Taproot Management LP's current position in RPRX?
As of Q1 2026, Taproot Management LP holds 129.59K shares of RPRX (ROYALTY PHARMA PLC), valued at $6.22M, representing 1.17% of its reported portfolio and ranking #16.
Has Taproot Management LP been buying or selling RPRX?
In the latest 13F filing (Q1 2026), Taproot Management LP reduced its position in RPRX.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.